Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Stroke Prevention

Published: 27 February 2023

  • Views:

    Views Icon 7980
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


This broadcast series 'Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?' will reappraise potent P2Y12 inhibitors, as evidence accumulates to support their broader use. At this juncture, there is still some uncertainty around patient selection, initiation and long-term management.


The fourth, and final, broadcast in this series, focused on Stroke Prevention. In this on-demand version of the live broadcast, Radcliffe Medical Education brings together a global faculty of experts in the field to look at current guidance, the landmark data, gaps in evidence and seeks to provide practical guidance.


Prof Clay Johnston (Harbor Health, Texas, US) chairs the proceedings, and is joined by Prof Philippe Gabriel Steg (Hospital Bichat-Claude Bernard, Paris, FR), Dr Shelagh Coutts (University of Calgary, CA) and Prof Jesse Dawson (University of Glasgow, UK) for a series of insightful presentations and discussions.


You can also catch up on previous broadcasts in this series:

This broadcast series is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

  • Recall recent trial data for antiplatelet therapies in secondary stroke prevention
  • Apply clinical judgement and trial data to develop optimal antiplatelet strategies in noncardioembolic stroke & TIA
  • Use guidance and recent trial data to formulate optimal antiplatelet strategies in large artery atherosclerosis
  • Confidently prescribe potent antiplatelet therapies by balancing ischaemic and bleeding risk

Target Audience

  • Neurologists
  • General Cardiologists
  • Interventional Cardiologists

More from this programme

Part 1

Potent Antiplatelets in Secondary Stroke Prevention: Where Do They Fit In?

Prof Clay Johnston provides an overview of the current guidance around the use of antiplatelet therapy in secondary stroke prevention.

Part 2

Potent P2Y12 Inhibitors in Large Artery Atherosclerosis: Which Patients Benefit?

Dr Shelagh Coutts focuses on large artery atherosclerosis and the clinical evidence behind potent P2Y12 inhibitors in this population.

Part 3

Risk Stratification in Secondary Stroke Prevention

Prof Jesse Dawson discusses the impact of genetics and race on outcomes, assessing the current requirement for genetic testing in specific patients.

Part 4

Balancing Ischaemic and Bleeding Risk: Insights From Cardiology

Prof Philippe Gabriel Steg provides insight into balancing risk through the eyes of a Cardiologist.

Part 5

Antiplatelet Strategies in Non-cardioembolic Ischaemic Stroke & TIA

Prof Jesse Dawson and Dr Shelagh Coutts each present a patient. Following this, the panel discuss treatment strategies for both, as well as answering audience questions. 

Faculty Biographies

Philippe Gabriel Steg

Philippe Gabriel Steg

Interventional Cardiologist

Prof Philippe Gabriel Steg works as an Interventional Cardiologist and is Director of the Coronary Care Unit of Hôpital Bichat, in Paris, France. 

Prof Steg’s research interests are in the field of coronary artery disease. He is a former member of the Board of the French Society of Cardiology, an honorary member of the Institut Universitaire de France, and received the silver medal of the European Society of Cardiology in 2011.

Prof Steg led the TAO and EUROMAX trials and is chairing or co-chairing several trials or registries, such as ODYSSEY-CV Outcomes, CLARIFY, THEMIS. Prof Steg has authored more than 650 articles in peer-reviewed international journals. He is a member of the editorial boards for Circulation, Circulation: Cardiovascular Interventions, the European Heart Journal, and the European Heart Journal – Cardiovascular Pharmacotherapy. He is deputy editor for the…

View full profile